Anzeige
Mehr »
Donnerstag, 20.11.2025 - Börsentäglich über 12.000 News
Baltikum rüstet massiv auf: 500 Mio. Abwehrprogramm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiPalo Alto Networks to acquire Chronosphere for $3.35 billion
MiSupermicro expands air-cooled AI server lineup with AMD Instinct MI355X
MiBank of Marin completes $595 million securities repositioning
MiASGN launches AI Factory framework to streamline enterprise AI adoption
MiMeihua International Medical to implement 1-for-100 reverse split
MiProthena presents TDP-43 CYTOPE data showing promise for ALS treatment
MiBelden appoints Adel Al-Saleh to board of directors
MiSS&C Technologies announces $0.27 quarterly dividend
MiAltigen and IPM form strategic partnership to cross-sell solutions
MiLineage subsidiary prices €700 million senior notes offering
MiAmgen's lung cancer drug imdelltra gets full FDA approval
MiPoll shows strong support for undergrounding power lines in California
MiSociedad Quimica y Minera price target raised to $77 by BMO Capital
MiNeedham downgrades SEMrush stock to Hold following Adobe acquisition
MiIBM and University of Dayton partner on semiconductor research
MiAbbott nears deal to acquire Exact Sciences stock, William Blair reiterates Outperform
MiLeerink Partners raises Zymeworks stock price target to $40 on transformation
MiOpenAI launches free ChatGPT for Teachers through June 2027
MiBlock shares three-year financial outlook at investor day
MiMotorola Solutions acquires AI video monitoring firm Blue Eye
MiTruist Securities lowers Lowe's stock price target to $256 on housing pressures
MiSalarius clarifies Nasdaq listing status, refutes S&P CapIQ error
MiDuke Energy names Katie Aittola as supply chain head
MiPiedmont prices $532.5 million tender offer for 9.25% senior notes
MiAgios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results